Company / Current Assets
4D Molecular Therapeutics, Inc. Current Assets History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$413.1M
FY2025
5-year range
$220.5M / $434.9M
FY2021-FY2025
Trend
-5.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $297M to $413M over the past 2 years.
Based on SEC 10-K filings.
$413M in FY2025 with a 5-year CAGR of +7.9%.
Improved from $297M to $413M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- +23.3%
- 5-Year CAGR
- +7.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +7.9%, indicating consistent growth.
- In FY2025, current assets decreased 5.0% year-over-year.
- Peak current assets was recorded in FY2024.
- Lowest current assets in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $413.1M | -5.0% |
| FY2024 | $434.9M | +46.6% |
| FY2023 | $296.6M | +34.5% |
| FY2022 | $220.5M | -14.0% |
| FY2021 | $256.3M | -9.3% |
| FY2020 | $282.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026